Enterprise Value

42.79M

Cash

40.72M

Avg Qtr Burn

-9.867M

Short % of Float

0.79%

Insider Ownership

0.19%

Institutional Own.

36.67%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Erivedge (vismodegib) Details
BCC (Basal Cell Carcinoma)

Approved

Quarterly sales

CA-4948 (emavusertib)+/- ibrutinib Details
Non-Hodgkin lymphoma, Cancer, Blood cancer

Phase 1/2

Data readout

CA-4948 (emavusertib) Details
Acute myeloid leukemia, Myelodysplastic syndrome, Blood cancer, Cancer

Phase 1/2

Data readout

Phase 1/2

Initiation

Phase 1

Data readout